Analysis
Berry Street, a US-based nutrition and metabolic-care startup, merged with India's Healthify to build a combined platform aimed at the growing GLP-1 drug market, TechCrunch reported. Financial terms of the deal were not disclosed. The combined company will operate under the Berry Street name in the US while retaining the Healthify brand in India and other international markets, run jointly by Berry Street founder Noah Kotlove and Healthify founder Tushar Vashisht as co-CEOs.
Berry Street operates a network of more than 2,000 clinics offering insurance-covered GLP-1 care alongside AI-powered nutrition coaching and meal tracking, and has served more than 200,000 people through partnerships with Amazon and Walmart; it raised $50 million in 2025 from Northzone, Sofina and FJ Labs. Healthify, backed by Khosla Ventures with more than $150 million raised total, offers AI and human fitness and nutrition coaching through its app, claims more than 45 million customers served, and recently expanded into US operations with its own GLP-1 programs -- meaning the two companies were already converging on the same market from opposite starting points (US clinical care versus India-scale consumer app) before formally combining.
- Berry Street -- 2,000+ clinic US nutrition/GLP-1 care network, $50M raised 2025, partnerships with Amazon and Walmart
- Healthify -- Khosla-backed Indian AI nutrition-coaching app, $150M+ raised, 45M+ customers served, recently expanded into US GLP-1 programs
- Noom, WeightWatchers (WW) -- established consumer weight-management competitors both racing to integrate GLP-1 care into existing subscription models
The deal's logic rests on a market projection both companies are explicitly building toward: JPMorgan estimates more than 30 million Americans will be on GLP-1 drugs by 2030 -- Pulse previously covered JPMorgan's broader healthcare and fintech projections -- a scale of adoption that has already reshaped consumer nutrition, fitness and telehealth competition. Berry Street's clinical, insurance-covered care model and Healthify's much larger consumer app base and India-market experience give the combined company both a US clinical delivery arm and a proven, larger-scale consumer product to pair it with -- a combination neither company had built independently.
The honest limitation is that undisclosed merger terms make it impossible to assess whether this is a genuine merger of equals or a stronger party effectively absorbing a weaker one, and neither company has published combined revenue or margin figures that would clarify the underlying financial logic of the deal beyond the stated market-opportunity rationale. What happens to Healthify's existing India user base under the new combined leadership structure, and whether the merged company raises a fresh round to fund integration, are the next concrete signals to watch.
